A Single-arm, Open-label Study of Ad-RTS-hIL-12 + Veledimex Following First-, Second-, or Third-Line Standard Treatment in Subjects With Locally Advanced or Metastatic Breast Cancer

Trial Profile

A Single-arm, Open-label Study of Ad-RTS-hIL-12 + Veledimex Following First-, Second-, or Third-Line Standard Treatment in Subjects With Locally Advanced or Metastatic Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs INXN 2001 (Primary) ; Veledimex
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors ZIOPHARM Oncology
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 11 Oct 2016 Preliminary results (n=8, data cut off 28 Apr 2016), presented at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top